NCT05870150 (CHANTS) is a NA clinical trial of Salmonella Typhimurium in Salmonella Infections, sponsored by Imperial College Healthcare NHS Trust.

Who is sponsoring NCT05870150?

NCT05870150 is sponsored by Imperial College Healthcare NHS Trust.

What drugs are being tested in NCT05870150?

Interventions in NCT05870150: Salmonella Typhimurium.

What condition does NCT05870150 study?

NCT05870150 studies Salmonella Infections, Salmonella Typhimurium, Non-typhoidal Salmonella (NTS), Invasive Non-Typhoidal Salmonella Disease, Communicable Disease, Infections, Bacterial, Enteric Fever (Not Typhoid), Gastroenteritis.

Is NCT05870150 still recruiting?

NCT05870150 is currently active, enrolled. Last updated 2 May 2025.

Last reviewed 2025-05-02 · How we verify

NCT05870150: CHANTS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Challenge Non-Typhoidal Salmonella (CHANTS) Study

Active, enrolled NA Last updated 2 May 2025

What this trial tests

NA trial testing Salmonella Typhimurium in Salmonella Infections in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 August 2023

Primary endpoint
28 February 2026

28 February 2026

Quick facts

Lead sponsor	Imperial College Healthcare NHS Trust
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	80
Start date	31 August 2023
Primary completion	28 February 2026
Estimated completion	28 February 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Salmonella Typhimurium — full drug profile →

Conditions studied

Salmonella Infections — all drugs for Salmonella Infections →
Salmonella Typhimurium — all drugs for Salmonella Typhimurium →
Non-typhoidal Salmonella (NTS) — all drugs for Non-typhoidal Salmonella (NTS) →
Invasive Non-Typhoidal Salmonella Disease — all drugs for Invasive Non-Typhoidal Salmonella Disease →

Sponsor

Imperial College Healthcare NHS Trust

Who can join

Adults 18 to 50, any sex, with Salmonella Infections or Salmonella Typhimurium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50 years. The primary objective of the study is to perform a dose escalation with two strains (ST19 or ST313) to determine the infectious dose required for 60-75% of volunteers to develop Salmonellosis using a composite diagnostic criterion. The secondary objectives of the study are to describe and compare the clinical and laboratory features following controlled human infection. It is hoped that the successful establishment of an NTS human challenge model can be used in the future to test candidate vaccines for NTS disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Protocol for the challenge non-typhoidal <i>Salmonella</i> (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK.
Smith C, Smith E, Rydlova A, Varro R, et al · · 2024 · cited 13× · PMID 38199617 · DOI 10.1136/bmjopen-2023-076477
Comparative phenotypic, genomic and transcriptomic characterisation of two <i>Salmonella</i> Typhimurium strains for a first-in-human challenge model
Smith C, Bzami A, Zhu X, White JA, et al · · 2025 · DOI 10.1101/2025.04.24.650425

Verify or expand the search:

Other recruiting trials for Salmonella Infections

Currently open trials in the same condition.

NCT06213506 — A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal S · Phase 2 · recruiting
NCT04694235 — Egg Intervention During Pregnancy in Indonesia · NA · active not recruiting

Other Imperial College Healthcare NHS Trust trials

Trials by the same sponsor.

NCT07474584 — OpRESTORE AI-Patient Navigator Study · NA · not yet recruiting
NCT07191678 — Mechanisms Affecting the Gut of Preterm Infants Receiving Blood Transfusion With Different Enteral Feed Interventions · recruiting
NCT06501846 — Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding. · NA · recruiting
NCT04904484 — A Safety Assessment of the iZephyr Hood for NIV in COVID-19 Patients · NA · unknown
NCT06355570 — Delirium After Cardiac Surgery in Intensive Care Units · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05870150 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College Healthcare NHS Trust
Last refreshed: 2 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing